Evommune, Inc. (EVMN) Press Releases

Recent Press Releases

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Date: Mon, 29 Jun 26 08:30:00 -0400

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Date: Thu, 07 May 26 16:05:00 -0400

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Date: Mon, 06 Apr 26 09:00:00 -0400

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Date: Thu, 05 Mar 26 16:01:00 -0500

Evommune Announces $125 Million Private Placement

Date: Thu, 12 Feb 26 20:30:00 -0500

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Date: Tue, 10 Feb 26 07:30:00 -0500

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Date: Thu, 11 Dec 25 16:05:00 -0500

Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Date: Fri, 07 Nov 25 16:05:00 -0500

Evommune Announces Pricing of its Initial Public Offering

Date: Wed, 05 Nov 25 19:45:00 -0500

Evommune Announces Commencement of Initial Public Offering

Date: Thu, 30 Oct 25 06:30:00 -0400